Recent Articles
Weekly Psychedelic Policy Briefing: October 12, 2026
FDA laid out how the first federally funded ibogaine trials could be run, with inpatient cardiac monitoring and a 10 mg/kg starting dose ceiling. Compass Pathways executives discussed pricing as the COMP360 NDA nears completion, and state cannabis regulators say DEA still hasn’t answered their rescheduling questions.
By Jack Gorsline
Filter
Psychedelic Churches Need Psychedelic Seminaries
The psychedelic field has built institutions for studying molecules, delivering therapies, and training facilitators. Paul…
By Paul Ryder, PhD
Tell the FDA What Psychedelic Care Should Look Like. You Have Until Monday.
A veteran’s recovery from 10-out-of-10 pain shows what the agency’s psychiatric model misses, and why…
By Joe Moore
When Psychedelic Experiences Turn into Crisis, Training Can Make All the Difference
Most psychedelic experiences pass without incident, but when one turns into a crisis, the people…
By By Sara Gael, MA, LPC
Weekly Psychedelic Policy Briefing: September 30th, 2026
DEA proposed placing five tryptamines in Schedule I, including the active compound in a postpartum…
By Jack Gorsline
Weekly Psychedelic Policy Briefing, September 21, 2026
The FDA heard 80 speakers on the future of psychedelic drugs, and its federal panel…
By Jack Gorsline
Health Canada Authorizes Optimi’s Natural Psilocybin Trial as House Bill Targets Botanical Drug Exclusivity
Optimi Health has Health Canada authorization for a Phase 2 trial of natural psilocybin in…